Gold bars to be exempt from tariffs, White House clarifies
NEWARK, NY—Thomas Louis Saeli, a director at Ultralife Corp (NASDAQ:ULBI), has increased his stake in the company by purchasing 5,000 shares of common stock. The shares were acquired at an average price of $5.44 per share, amounting to a total investment of $27,200. Following the transaction, Saeli now owns 85,000 shares directly. The timing appears opportune, as InvestingPro data shows the stock has gained over 20% in the past week, though it remains significantly below its 52-week high of $12.40.
The acquisition took place over two days, with 2,995 shares purchased on May 13 at $5.4316 per share and 2,005 shares on May 14 at $5.4525 per share. This move reflects Saeli’s continued confidence in the company’s prospects. The company maintains strong financial health with a current ratio of 3.22, indicating robust liquidity. According to InvestingPro analysis, Ultralife appears undervalued, with 8 additional ProTips available to subscribers through the comprehensive Pro Research Report.
In other recent news, Ultralife Corporation reported its Q1 2025 financial results, revealing a mixed performance. The company achieved a revenue of $50.7 million, surpassing the forecasted $48 million, marking a 21% increase year-over-year. However, the earnings per share (EPS) fell short of expectations, coming in at $0.11 compared to the anticipated $0.14. Despite the EPS miss, Ultralife’s revenue growth was driven by a significant increase in government defense sales, which rose by 53.6%. The company also highlighted the positive contribution margin from its recent acquisition of Electrochem, suggesting a favorable impact on profitability. Analysts from The Benchmark Company and Sidoti and Company noted the company’s strategic focus on expanding its product line and strengthening its position in international military markets. Ultralife’s management expressed optimism about a recovery in medical battery sales in the latter half of 2025 and emphasized ongoing new product development efforts. The company remains vigilant about potential supply chain disruptions and macroeconomic pressures that could affect its cost structures and margins.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.